Taken together, our results provide proof of principle that ERK5-targeted inhibition may be a promising therapeutic approach to eliminate drug-resistant cancer stem-like cells and improve colon cancer treatment. This evidence concerns the gene MAPK7 and malignant colon neoplasm.